Pipeline Insight: Lung Cancers Overview – Intensive R&D activity but little improvement in patient outcomes

Typ der Studie:	Marktstudie
Jahrgang:	12/2010
Herausgeber:	Datamonitor
Sprachversion:	Englisch
Verfügbarkeit:	Lieferbar

Preis**
(Lieferformat):

11.400,00$ netto SlidePack

Versandkostenfrei

** WICHTIG:
Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%).

Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs.

Zahlen und Fakten zur Studie:

167+28 seiten

Inhalt der Studie:

Mehr über diese Studie

Introduction

Despite advances in therapy, prognosis for non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) remains poor. The late-phase pipeline holds little promise for considerable improvements in patient outcomes however; these drugs are forecast to realize sales of over $3.1 billion by 2019. Many unmet needs remain unfulfilled; therefore significant commercial opportunities exist.
Features and benefits

* Identify key drugs and companies within the lung cancers pipeline based on sales forecasts to 2019 and Datamonitor drug assessment* Characterize unmet need and poorly served patient groups within lung cancer and assess the potential for pipeline products to fulfill them* Assess the shifting lung cancer market dynamic and how future treatment will incorporate pipeline products
Highlights

There are 134 drugs in development for non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC). Molecular targeted therapies constitute the bulk (73%) of the pipeline. By contrast, cytotoxic therapies and immunotherapeutic/immunomodulatory drugs (including therapeutic cancer vaccines) account for only 13% of the pipeline each.The treatment of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) is characterized by a high level of unmet need, most notably for more effective therapies to improve patient survival. This, together with the large patient population, translates into a high commercial potential, which is driving extensive R&D activity.Within the pipeline, 84% of drugs are seeking approval for the treatment of NSCLC and 16% for SCLC. The greater interest in NSCLC is not surprising, given that this indication is not only characterized by a high level of unmet need but also from a large and growing patient population. Therefore, NSCLC has the greatest commercial potential.
Your key questions answered

* Examination of the lung cancers pipeline with in-depth clinical and commercial profiles of Phase III candidates* Seven major pharmaceutical market sales forecasts for Phase III pipeline products through to 2019 with product-specific assumptions* Segmentation and analysis of the current lung cancers pipeline by developmental phase, drug class and company* Insight and analysis of market potential including commercial opportunity, epidemiology and discussion of unmet needs

[Studien Infos ausblenden]

Inhaltsverzeichnis

Hinweis:

* Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs

Warenkorb

Pipeline Insight: Lung Cancers Overview – Intensive R&D activity but little improvement in patient outcomes

Copyright 2012 by dynamic technologies GmbH

	Weitere Studien von Datamonitor: Treatment Algorithms: Type 2 Diabetes – Novel classes drive fragmentation of treatment choices in type 2 diabetes What Consumers Want: Checking Accounts in Canada 2011 Epidemiology: Bipolar Disorders – Population growth to mean more patients with bipolar disorders Male Grooming in India: Responses to Emerging Needs and Changing Behavior Product Insights: Dairy in the US [Mehr...]